Rioux Josée, Edwards Jenny, Bresee Lauren, Abu-Ulba Adrian, Yu Stephen, Dersch-Mills Deonne, Wilson Ben
BScPharm, ACPR, is with Pharmacy Services, Alberta Health Services, Calgary, Alberta.
BScPharm, ACPR, MSc, PhD, is with the Department of Community Health Sciences, Cumming School of Medicine, and the O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta; and the Canadian Agency for Drugs and Technologies in Health, Ottawa, Ontario.
Can J Hosp Pharm. 2017 Mar-Apr;70(2):107-112. doi: 10.4212/cjhp.v70i2.1642. Epub 2017 Apr 28.
Nasal-swab screening for methicillin-resistant (MRSA) has a quicker turnaround time than other bacterial culture methods, with results available within 24 h. Although MRSA nasal-swab screening is not intended to guide antimicrobial therapy, this method may give clinicians additional information for earlier tailoring of empiric antimicrobial agents.
To describe the diagnostic characteristics of nasal-swab screening in predicting MRSA infections in hospitalized patients receiving empiric treatment with IV vancomycin.
A retrospective observational chart review was conducted for newly admitted adult patients of the Peter Lougheed Centre in Calgary, Alberta, who were treated empirically with IV vancomycin from January to October 2015 and who underwent nasal-swab screening for MRSA. The diagnostic characteristics of nasal-swab screening were calculated in relation to corresponding culture results for samples collected on admission.
For the 273 patients included in this study, nasal-swab screening for MRSA showed the following diagnostic characteristics in relation to bacterial culture results: sensitivity 58.3% (95% confidence interval [CI] 28.6%-83.5%), specificity 93.9% (95% CI 90.0%-96.3%), positive predictive value 30.4% (95% CI 14.1%-53.0%), negative predictive value 98.0% (95% CI 95.1%-99.3%), positive likelihood ratio 9.5 (95% CI 4.9-18.7), and negative likelihood ratio 0.4 (95% CI 0.2-0.9).
Given the high specificity of this rapid method, clinicians should ensure that patients who are receiving empiric treatment for MRSA infection and who have a positive result on nasal-swab screening continue to receive MRSA coverage until culture results are available. In addition, the high negative predictive value and positive likelihood ratio for nasal-swab screening in a low-prevalence setting suggest that a negative result significantly reduces the probability of MRSA infection. Although nasal-swab screening for MRSA is currently used for determining isolation precautions, this method also had utility in helping clinicians to predict the probability of MRSA infection and in guiding decisions about antimicrobial therapy.
耐甲氧西林金黄色葡萄球菌(MRSA)的鼻拭子筛查比其他细菌培养方法周转时间更快,24小时内即可获得结果。虽然MRSA鼻拭子筛查并非用于指导抗菌治疗,但该方法可为临床医生提供更多信息,以便更早地调整经验性抗菌药物。
描述鼻拭子筛查对接受静脉万古霉素经验性治疗的住院患者中MRSA感染的诊断特征。
对艾伯塔省卡尔加里市彼得·洛希德中心新入院的成年患者进行回顾性观察图表审查,这些患者在2015年1月至10月期间接受静脉万古霉素经验性治疗,并接受了MRSA鼻拭子筛查。根据入院时采集样本的相应培养结果计算鼻拭子筛查的诊断特征。
本研究纳入的273例患者中,MRSA鼻拭子筛查相对于细菌培养结果显示出以下诊断特征:敏感性58.3%(95%置信区间[CI]28.6%-83.5%),特异性93.9%(95%CI 90.0%-96.3%),阳性预测值30.4%(95%CI 14.1%-53.0%),阴性预测值98.0%(95%CI 95.1%-99.3%),阳性似然比9.5(95%CI 4.9-18.7),阴性似然比0.4(95%CI 0.2-0.9)。
鉴于这种快速方法具有较高的特异性,临床医生应确保对接受MRSA感染经验性治疗且鼻拭子筛查结果为阳性的患者,在获得培养结果之前继续给予MRSA覆盖。此外,在低患病率情况下,鼻拭子筛查的高阴性预测值和阳性似然比表明阴性结果可显著降低MRSA感染的概率。虽然目前MRSA鼻拭子筛查用于确定隔离预防措施,但该方法在帮助临床医生预测MRSA感染概率和指导抗菌治疗决策方面也具有实用性。